Typhoid Fever
39
1
2
31
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 39 trials
100.0%
+13.5% vs benchmark
28%
11 trials in Phase 3/4
26%
8 of 31 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 31 completed trials
Clinical Trials (39)
Vellore Typhoid Vaccine Impact Trial
This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever
The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
Induction of Gut Permeability by an Oral Vaccine
Diagnosis and Staging of Typhoid Fever Using Surface-enhanced Raman Spectroscopy Liquid Biopsy
ZyVac-TCV Bangladesh Study
Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana
Evaluation Study of DPP® Typhoid Assay
Global Genomic and Proteomic Profiling of African Children With Typhoid Fever
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
Understanding Typhoid Disease After Vaccination
Effectiveness of a Typhoid Conjugate Vaccine in DRC
TyVECO: Surveillance Protocol
Vaccines Against Salmonella Typhi
Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study
Commercial Typhoid Tests Validation Trial
Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participants